Cullinan Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cullinan Therapeutics's earnings have been declining at an average annual rate of -10%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 11% per year.
Key information
-10.0%
Earnings growth rate
79.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -11.0% |
| Return on equity | -34.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Oct 08Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
Jun 30Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 05Cullinan initiated Buy at H.C. Wainwright on pipeline strength
Feb 02Revenue & Expenses BreakdownBeta
How Cullinan Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -153 | 42 | 148 |
| 30 Sep 23 | 0 | -156 | 43 | 135 |
| 30 Jun 23 | 0 | -142 | 42 | 120 |
| 31 Mar 23 | 0 | 65 | 41 | 120 |
| 31 Dec 22 | 0 | 111 | 40 | 92 |
| 30 Sep 22 | 0 | 105 | 40 | 92 |
| 30 Jun 22 | 0 | 113 | 36 | 85 |
| 31 Mar 22 | 0 | -78 | 32 | 70 |
| 31 Dec 21 | 19 | -66 | 29 | 58 |
| 30 Sep 21 | 19 | -61 | 28 | 60 |
| 30 Jun 21 | 19 | -54 | 24 | 57 |
| 31 Mar 21 | 19 | -47 | 21 | 51 |
| 31 Dec 20 | 0 | -52 | 17 | 43 |
| 30 Sep 20 | 0 | -28 | 6 | 24 |
| 30 Jun 20 | 0 | -25 | 6 | 19 |
| 31 Mar 20 | 0 | -21 | 6 | 17 |
| 31 Dec 19 | 0 | -21 | 5 | 17 |
Quality Earnings: CGEM is currently unprofitable.
Growing Profit Margin: CGEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CGEM is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare CGEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CGEM has a negative Return on Equity (-34.17%), as it is currently unprofitable.